摘要
目的探讨重组人干扰素α-1b联合布地奈德雾化治疗小儿支气管肺炎的临床疗效及其安全性。方法选取连云港市妇幼保健院2017年7月-2019年1月收治的小儿支气管肺炎患儿80例,采用随机数字表法分为对照组和治疗组,各40例。对照组给予常规对症治疗,治疗组在对照组基础上给予重组人干扰素α-1b联合布地奈德雾化治疗。两组均连续治疗5 d。比较两组临床疗效,治疗后肺啰音消失时间、退热时间、喘息消失时间、咳嗽消失时间、住院时间、不良反应发生率。结果治疗组总有效率高于对照组,肺啰音消失时间、退热时间、喘息消失时间、咳嗽消失时间、住院时间短于对照组,不良反应发生率低于对照组(P<0.05)。结论重组人干扰素α-1b联合布地奈德雾化治疗小儿支气管肺炎的临床疗效确切,可缩短患儿症状消失时间及住院时间,且安全性较高。
Objective To explore the clinical efficacy and safety of interferonα-1 b combined with budesonide for bronchopneumonia in children.Methods A total of 80 cases of children with bronchitis were selected from July 2017 to January 2019 in Lianyungang Maternal and Child Health Hospital,which were divided into control group and treatment group according to random number table,40 cases each of group.The control group was given routine symptomatic treatment,and the treatment group was given interferonα-1 b combined with budesonide atomization based on the control group.Both groups were treated for 5 days.The clinical efficacy,after treatment of the disappearance time of rales,fever,wheezing,cough,hospitalization time and adverse reactions were compared between the two groups.Results The total effective rate of the treatment group was higher than the control group,the disappearance time of rales,fever,wheezing,cough and hospitalization time were shorter than the control group,and the incidence rate of adverse reactions was lower than the control group(P<0.05).Conclusion The clinical efficacy of interferonα-1 b combined with budesonide atomization for bronchopneumonia in children is accurate,which can shorten the time of symptom disappearance,shorten the time of hospitalization and with high safety.
作者
侍苏杰
SHI Sujie(Lianyungang Maternal and Child Health Hospital,Lianyungang 222000,China)
出处
《临床合理用药杂志》
2019年第36期5-6,共2页
Chinese Journal of Clinical Rational Drug Use
